Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8615637 | Clinical Lymphoma Myeloma and Leukemia | 2018 | 9 Pages |
Abstract
In a large database capturing a heterogeneous patient population and varied treatment patterns reflecting routine clinical care, we found a clinical benefit for continued longer DOT at first relapse. Despite the emerging paradigm favoring continuous therapy, second-line progression-free survival (utilizing TTNT as the proxy) was more than twofold longer than the DOT. Understanding the barriers to extended DOT could help to improve the outcomes for RRMM patients.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Parameswaran Hari, Dorothy Romanus, Antonio Palumbo, Katarina Luptakova, Robert M. Rifkin, Linh Mai Tran, Aditya Raju, Eileen Farrelly, Stephen J. Noga, Marlo Blazer, Ajai Chari,